Paediatric Therapeutic Development Workshop on rhabdomyosarcoma
Joseph S. Baxter, Claudia Montiel Equihua, Jan J. Molenaar, Jamie Aye, Gianni Bisogno, Patricia Blanc, Willemijn Breunis, Julia Chisholm, Jacquelyn Crane, Sam Daems, Laura Danielson, Bram de Wilde, Adam D. Durbin, Felipe Galvez-Cancino, Patrizia Gasparini, Birgit Geoerger, Simone Graham, Bass Hassan, Mark E. Hatley, Delphine Heenen, Christine M. Heske, Simone Hettmer, Elizabeth Hookham, Peter Houghton, Pamela Kearns, Charles Keller, Javed Khan, Fiona Kinnis, David Langenau, Geffen Lass, Corinne Mary Linardic, Leo Mascarenhas, Michael T. Meister, Jonathan Metts, Véronique Minard-Colin, Sapna Oberoi, Daniela Palacios, Abbe Pannucci, Seema Patel, Sheena Patel · 2026
Read Paediatric Therapeutic Development Workshop on rhabdomyosarcoma by Joseph S. Baxter, Claudia Montiel Equihua, Jan J. Molenaar, Jamie Aye, Gianni Bisogno, Patricia Blanc, Willemijn Breunis, Julia Chisholm, Jacquelyn Crane, Sam Daems, Laura Danielson, Bram de Wilde, Adam D. Durbin, Felipe Galvez-Cancino, Patrizia Gasparini, Birgit Geoerger, Simone Graham, Bass Hassan, Mark E. Hatley, Delphine Heenen, Christine M. Heske, Simone Hettmer, Elizabeth Hookham, Peter Houghton, Pamela Kearns, Charles Keller, Javed Khan, Fiona Kinnis, David Langenau, Geffen Lass, Corinne Mary Linardic, Leo Mascarenhas, Michael T. Meister, Jonathan Metts, Véronique Minard-Colin, Sapna Oberoi, Daniela Palacios, Abbe Pannucci, Seema Patel, Sheena Patel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13427830.txt.
Description
Joseph S. Baxter and a very large group of specialists report, in a 2026 workshop summary, where drug development for a childhood muscle cancer should go next. Rhabdomyosarcoma is the commonest soft tissue sarcoma of childhood. Survival tops 90 percent for the lowest-risk cases yet sits near 20 to 30 percent when the cancer has spread. The workshop weighed new drug ideas against what is known about the tumor's drivers.
Top priorities include drugs that destroy the abnormal fusion proteins that drive many of these tumors, and degraders that chew up helper proteins those fusions need. Antibody-drug conjugates aimed at a surface marker called B7-H3 also ranked high. Combination testing, and simply gaining access to candidate drugs, were named as practical hurdles. Funders and trial designers get a ranked roadmap.
Catalog record
| CREATOR | Joseph S. Baxter, Claudia Montiel Equihua, Jan J. Molenaar, Jamie Aye, Gianni Bisogno, Patricia Blanc, Willemijn Breunis, Julia Chisholm, Jacquelyn Crane, Sam Daems, Laura Danielson, Bram de Wilde, Adam D. Durbin, Felipe Galvez-Cancino, Patrizia Gasparini, Birgit Geoerger, Simone Graham, Bass Hassan, Mark E. Hatley, Delphine Heenen, Christine M. Heske, Simone Hettmer, Elizabeth Hookham, Peter Houghton, Pamela Kearns, Charles Keller, Javed Khan, Fiona Kinnis, David Langenau, Geffen Lass, Corinne Mary Linardic, Leo Mascarenhas, Michael T. Meister, Jonathan Metts, Véronique Minard-Colin, Sapna Oberoi, Daniela Palacios, Abbe Pannucci, Seema Patel, Sheena Patel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 79194 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |